Syros Pharmaceuticals (United States)

Alternate names: Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.

ROR: 05nj87k55

OpenAlex ID: I4405273325

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

2017 · José Baselga, Seock-Ah Im, et al. · The Lancet Oncology · 546

Quantitative ChIP-Seq Normalization Reveals Global Modulation of the Epigenome

2014 · David A. Orlando, Mei Wei Chen, et al. · Cell Reports · 506

PDF

Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy

2019 · Marie-Eve Beaulieu, Toni Jauset, et al. · Science Translational Medicine · 214

Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7

2019 · Shanhu Hu, Jason J. Marineau, et al. · Cancer Research · 153

Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist

2017 · Michael R. McKeown, M. Ryan Corces, et al. · Cancer Discovery · 134

Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription

2020 · Jenna K. Rimel, Zachary C. Poss, et al. · Genes & Development · 101

PDF

Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7

2021 · Jason J. Marineau, Kristin B. Hamman, et al. · Journal of Medicinal Chemistry · 97

Molecular taxonomy of myelodysplastic syndromes and its clinical implications

2024 · Elsa Bernard, Robert P. Hasserjian, et al. · Blood · 95

PDF

Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia

2016 · Neerav Shukla, Cynthia Wetmore, et al. · Blood · 93

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

2017 · B. Pistilli, T. Pluard, et al. · Breast Cancer Research and Treatment · 65

A glycoprotein B-neutralizing antibody structure at 2.8 Å uncovers a critical domain for herpesvirus fusion initiation

2020 · Stefan L. Oliver, Yi Xing, et al. · Nature Communications · 47

PDF

Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L

2017 · Nigel J. Waters · European Journal of Drug Metabolism and Pharmacokinetics · 42

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

2022 · Stéphane de Botton, Thomas Cluzeau, et al. · Blood Advances · 41

PDF

ΔNp63/p73 drive metastatic colonization by controlling a regenerative epithelial stem cell program in quasi-mesenchymal cancer stem cells

2022 · Arthur W. Lambert, Christopher Fiore, et al. · Developmental Cell · 35

PDF

Implications for Metabolite Quantification by Mass Spectrometry in the Absence of Authentic Standards

2017 · Panos Hatsis, Nigel J. Waters, et al. · Drug Metabolism and Disposition · 33

Nucleosome-directed replication origin licensing independent of a consensus DNA sequence

2022 · Sai Li, Michael R. Wasserman, et al. · Nature Communications · 32

PDF

Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children

2020 · Andrew DJ. Pearson, Kimberly Stegmaier, et al. · European Journal of Cancer · 26

PDF

The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion

2021 · Stefan L. Oliver, Yi Xing, et al. · PLoS Pathogens · 24

Abstract PD7-12: Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells

2019 · C Guarducci, A Nardone, et al. · Cancer Research · 18

Antitumor synergy with SY-1425, a selective RARα agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia

2018 · Michael R. McKeown, Liv Johannessen, et al. · Haematologica · 18

PDF

TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network

2025 · Taylor Jones, Junjie Feng, et al. · Science Advances · 14

MICAL2 Promotes Pancreatic Cancer Growth and Metastasis

2025 · Bharti Garg, Sohini Khan, et al. · Cancer Research · 14

PDF

Abstract 4421: SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo

2019 · Shanhu Hu, Jason Marineau, et al. · Cancer Research · 14

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS

2025 · Amy E. DeZern, Sylvain Thepot, et al. · Blood Advances · 13

PDF

Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression

2023 · Eytan M. Stein, Stephane de Botton, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 11

Works count: 110

Citation count: 14,880